Clinical trials
Completed Gonorrhea trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
73 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 4 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 6 |
| 2014 | 5 |
| 2015 | 4 |
| 2016 | 3 |
| 2017 | 5 |
| 2018 | 5 |
| 2019 | 10 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 73 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 14 |
| Northwestern University | 4 |
| University of California, San Francisco | 4 |
| University of Pittsburgh | 4 |
| University of Washington | 3 |
| Centers for Disease Control and Prevention | 2 |
| Columbia University | 2 |
| Duke University | 2 |
| Gen-Probe, Incorporated | 2 |
| GlaxoSmithKline | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Gonorrhea | 73 |
| Chlamydia Infections | 41 |
| Sexually Transmitted Diseases | 19 |
| Trichomonas Infections | 10 |
| HIV Infections | 9 |
| Syphilis | 7 |
| Acquired Immunodeficiency Syndrome | 6 |
| Disease | 3 |
| Emergencies | 3 |
| Vaginosis, Bacterial | 3 |
Trials
Showing 1 to 25 of 73. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.